SANTA ANA, Calif. – California says in a lawsuit filed Friday that pharmaceutical company Boehringer Ingelheim illegally paid rival Barr Laboratories over $120 million to delay the release of a generic version of the stroke-preventing drug Aggrenox.
Other defendants in the lawsuit filed by Orange County District Attorney Tony Rackauckas include Boehringer Ingelheim Pharma; Boehringer Ingelheim International; Teva Pharmaceuticals USA; Barr Pharmaceuticals; Barr Laboratories; Duramed Pharmaceuticals; and Duramed Pharmaceuticals Sales Corp.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.